multiple sclerosis

Eleven potential blockbuster drugs offer hope, threaten budgets

Crowned by a potential cure for severe hemophilia A, which could become the most expensive drug ever, a new list of 11 medicines expected to generate $1 billion-plus in annual sales by the end of 2024 or earlier throws into stark relief the growing tension between medical innovation and society’s ability to pay for it. […]

Roche’s Ocrevus to dominate the multiple sclerosis market

As it enters the market, Ocrevus (ocrelizumab) is a drug set not only to top the multiple sclerosis (MS) field, but also to be 2017’s biggest future-blockbuster entrant. The 2017 edition of the annual Drugs to Watch report forecasts that seven new drugs including Ocrevus will enter the market in 2017 and achieve blockbuster sales of more than 1 billion by 2021, as evaluated by consensus sales forecast data from Clarivate Analytics Cortellis Competitive Intelligence (source Thomson Reuters I/B/E/S).